Pfizer has thrown in the towel on inhalable insulin.
Cafe Du Monde will continue to market inhalable sugar.
(Update: Ooh! Snap! Nektar Therapeutics, Pfizer’s partner on Exubera, didn’t find out about Pfizer’s decision to bail on the drug until the announcement this morning!)